Thermosome Announces Further Dose Escalation in Phase I Trial with Lead Program THE001
February 06, 2024 04:00 ET
|
AKAMPION
- First dose level rated as safe by independent Data Safety Monitoring Board- Second dose level to be administered according to plan- THE001 designed as targeted tumor treatment independent...
Thermosome Establishes High-Profile Clinical Advisory Board
September 19, 2023 04:00 ET
|
AKAMPION
Leveraging the transformative potential of TSL-based tumor targeting Supporting the progress of Thermosome's clinical candidate THE001 Munich, Germany – September 19, 2023 – Thermosome, a drug...
Soft Tissue Sarcoma Market to Propel by 2032, Predicts DelveInsight | Key Companies in the Market - Monopar, Jazz, Tracon, C4, Eli Lilly, Epizyme, Ipsen, GlaxoSmithKline, Salarius, Merck, Agenus, Mirati
August 03, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Soft Tissue Sarcoma Market to Propel by 2032, Predicts DelveInsight | Key Companies in the Market - Monopar, Jazz, Tracon, C4, Eli Lilly, Epizyme,...
Thermosome Announces Participation in IMAGIO Consortium to Improve Cancer Treatment
June 20, 2023 04:00 ET
|
AKAMPION
IMAGIO consortium of clinical partners coordinated by Philips receives EUR 24 million grant from the Innovative Health Initiative (IHI) and additional funding from industry partners to support the...
Thermosome Announces First Patient Dosed in Phase I Trial with Lead Program THE001
May 24, 2023 04:00 ET
|
AKAMPION
- Addressing high unmet medical need in locally advanced soft tissue sarcoma- Targeted tumor treatment independent of specific molecular targets or tumor subtypes Munich, Germany – May 24,...
Thermosome Receives Regulatory Approval for First-In-Human Trial with its Lead Program THE001
March 28, 2023 03:45 ET
|
AKAMPION
- Novel compound for targeted tumor therapy to be evaluated in patients with soft tissue sarcoma- First patients to be enrolled in Q2, 2023 Munich, Germany – March 28, 2023 – Thermosome, a...
Monopar Announces First Patient Dosed in Phase 1b Trial Evaluating Camsirubicin for the Treatment of Advanced Soft Tissue Sarcoma
October 27, 2021 08:05 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Philogen Provides Corporate Update
September 29, 2021 04:58 ET
|
Philogen
Philogen Provides Corporate Update Nidlegy™ and Fibromun on track with planned timelines in pivotal clinical trialsUse of Nidlegy™ in non-melanoma skin cancer expanded in Phase II clinical...
The soft tissue sarcoma market is projected to be worth over USD 420 million in 2030, growing at an annualized rate of 27.54% during the period 2021-2030, claims Roots Analysis
September 22, 2021 09:00 ET
|
Roots Analysis
London, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Soft Tissue Sarcoma Market: Focus on Angiosarcoma, Chondrosarcoma, and Liposarcoma Market, 2021-2030” report...
FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (devimistat) for Treatment of Soft Tissue Sarcoma
October 29, 2020 09:30 ET
|
Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics announced today that...